Medtronic cardiovascular organic growth in Q1

View on Kalshi Expiration: September 1, 2026 Updated: August 9, 2026 Financials Companies

By Melvin Tercan, Octagon Research Editor

Short Answer

The model assigns meaningfully higher odds than the market for Medtronic's cardiovascular organic growth in Q1 to be Above 6% (24.7% model vs 0.0% market). This is driven by Medtronic's Q1 FY2027 overall organic revenue growth guidance of 11.5% to 12.0%, significantly boosted by an extra selling week, and the Cardiovascular segment's consistent historical outperformance.

1. Market Behavior & Drivers

This market's price action displays a dramatic, near-vertical increase over a two-day period. The implied probability of Medtronic's Q1 FY2027 cardiovascular organic growth meeting the market's criteria moved from a low of 1.0% on August 7, 2026, to 94.0% by August 9, 2026. This represents an almost complete reversal in outlook. The provided context, however, offers no clear catalyst for this extreme price movement, as it primarily notes that the relevant financial data has not yet been released.

The most critical feature of this market is the complete absence of trading volume. With zero contracts traded, the price changes reflect shifts in unfilled bids and asks, not executed transactions. This indicates a highly illiquid market with no active participation or capital commitment behind the price levels shown. The lack of volume means traditional technical indicators like support and resistance levels are not meaningful.

The chart's price trajectory suggests a rapid shift in sentiment from overwhelmingly negative to highly positive. However, this reading is superficial. Given the zero-volume environment, the price cannot be interpreted as a reliable consensus forecast. It likely reflects the actions of a single participant setting an initial low offer and then a subsequent high bid, without any counter-party engaging to establish a traded price. The market is effectively unformed.

Medtronic's Q1 FY2027 cardiovascular growth above 6% is likely, given 11.5-12.0% overall guidance.
The segment historically outperforms company growth, further boosted by an extra Q1 selling week.
Strong product drivers like Cardiac Ablation Solutions are expected to support robust performance.

Who Wins and Why

Outcome	Market	Model	Why
Outcome	—	—	Insufficient data

Current Context

Medtronic's Q1 FY2027 cardiovascular growth is not yet reported. As of August 9, 2026, Medtronic has not released its Q1 FY2027 financial results; consequently, the cardiovascular organic revenue growth figure for this period is unavailable ^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}. The company is scheduled to report its Q1 FY2027 results on Tuesday, September 1, 2026, at 5:45 a.m. Central Time, with a webcast following at 6:45 a.m. Central Time ^{[^]}^{[^]}. The first fiscal quarter concluded on Friday, July 31, 2026 ^{[^]}.

Overall Q1 FY2027 organic growth guidance is available, not cardiovascular. Medtronic's FY2027 organic revenue growth guidance includes an approximate 11.5% to 12.0% organic growth for the first quarter overall, as stated in FY2026 Q4 materials ^{[^]}^{[^]}. However, the company has not explicitly provided a separate Q1 FY2027 cardiovascular organic revenue growth figure ^{[^]}. For historical context, the most recently reported cardiovascular organic growth was 7.00% in Q1 FY2026 ^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}. Medtronic's cardiovascular segment delivered 10.10% organic growth in Q4 FY2026, driven by factors such as CAS growth and the expanded CE Mark for Affera/Sphere-9 in ventricular arrhythmias ^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}^{[^]}. An external market is available for "Above 9% cardiovascular organic revenue growth in Q1 2027", but this is not an official company KPI ^{[^]}.

2. Price Chart

Historical Price (Probability)

Outcome probability

Date

3. Market Data

Contract Snapshot

For a given percentage threshold, a YES resolution occurs if Medtronic's cardiovascular organic growth in Q1 is strictly above that specified percentage. A NO resolution occurs if the growth is at or below the specified percentage. The market closes for trading on September 1, 4:00 PM EDT, with a maximum payout date of December 29, 2026. The provided content does not detail specific data sources or additional settlement conditions.

Available Contracts

Market options and current pricing

Outcome bucket	Yes (price)	No (price)	Last trade probability

Market Discussion

Medtronic's cardiovascular organic growth was 7.0% in Q1 FY2026, significantly boosted by nearly 50% revenue growth in its Cardiac Ablation Solutions (CAS) segment, largely attributed to pulsed field ablation products ^{[^]}^{[^]}^{[^]}. For Q1 FY2027, the company has announced guidance for approximately 11.5% to 12% organic growth, a projection analysts support, citing continued CAS momentum and strategic investments made in June 2026 ^{[^]}^{[^]}^{[^]}. Current market odds suggest a 70% chance of growth exceeding 8% ^{[^]}.

4. Trader Dashboard

A deterministic, per-market integrity scorecard computed from order-book and price data. Higher is better for Trader Trust, Liquidity, Move Quality and Resolution; higher means more risk for Quote Risk and Avoid Risk.

Above 6%PrimaryTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—

Move Quality—No significant movehigh confidence

Factor

Above 7%Trader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—